BioSpace News Archive

Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction.

LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its second quarter earnings release after the market closes on Tuesday, August 9, 2022.

The global insulin market size is expected to be worth around USD 23.57 billion by 2030 from valued at USD 20.55 billion in 2021 and anticipated to grow at a CAGR of 1.54% during the forecast period 2022 to 2030.

The global downstream processing market size is predicted to be worth around US$ 24.2 billion by 2030 from valued at US$ 6.8 Bn in 2020, expanding growth at a rapid pace from 2020 to 2030.

According to Vision Research Reports, North America OTC health products market size is expected to be worth around USD 106.9 billion by 2030 and poised to grow at a CAGR of 6.05% during the forecast period 2022 to 2030.

The global small molecule API market size is projected to worth around USD 282.85 billion by 2030 from valued at USD 175.52 billion in 2021, growing at a CAGR of 5.44% during the forecast period 2022 to 2030.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects treated in the Phase 1.

Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, research and development pipeline, and technology initiatives to expand its reach and make it easier for healthcare providers and their patients to benefit from genetic insights.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation[1].

Avantor, Inc. has appointed veteran strategy and M&A executive, Kitty Sahin, to the newly created role of EVP, Strategy and Corporate Development, effective immediately.